Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 939.84M | 1.06B | 1.08B | 957.70M | 847.39M | 745.38M |
Gross Profit | 235.23M | 270.45M | 280.67M | 277.63M | 263.60M | 280.15M |
EBITDA | 56.63M | 100.46M | 125.48M | 118.07M | 116.00M | 120.59M |
Net Income | 5.43M | 41.56M | 38.10M | 22.74M | 30.32M | 11.72M |
Balance Sheet | ||||||
Total Assets | 1.40B | 1.42B | 1.34B | 1.26B | 1.21B | 1.26B |
Cash, Cash Equivalents and Short-Term Investments | 254.85M | 249.60M | 194.03M | 256.17M | 198.41M | 261.46M |
Total Debt | 434.48M | 402.44M | 354.43M | 290.68M | 238.96M | 305.78M |
Total Liabilities | 701.11M | 710.04M | 638.30M | 569.15M | 493.19M | 576.86M |
Stockholders Equity | 616.42M | 639.79M | 619.03M | 615.58M | 616.90M | 591.80M |
Cash Flow | ||||||
Free Cash Flow | -7.83M | 94.73M | -63.25M | 93.64M | 22.88M | 113.66M |
Operating Cash Flow | -21.66M | 135.82M | 42.28M | 186.55M | 81.20M | 123.58M |
Investing Cash Flow | 40.88M | -27.64M | -120.63M | -84.05M | -50.84M | -2.76M |
Financing Cash Flow | -74.00M | -47.61M | 4.37M | -51.31M | -87.20M | 25.03M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | HK$496.80M | 20.12 | 3.98% | ― | -15.96% | 32.95% | |
60 Neutral | HK$380.15M | 8.41 | 6.37% | 1.05% | -16.52% | -8.87% | |
56 Neutral | HK$303.25M | 50.51 | 0.86% | 6.22% | -10.78% | -82.81% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$536.71M | ― | -40.38% | ― | -43.46% | -96.48% | |
49 Neutral | HK$263.73M | 76.19 | -4.89% | 23.73% | -1.68% | -111.10% |
Kingworld Medicines Group Ltd. reported a significant decline in its financial performance for the first half of 2025, with revenue dropping by 23% and profit attributable to owners of the company turning into a loss compared to the same period in 2024. The company’s gross profit margin slightly decreased, and overall profit for the period fell by 74.9%, reflecting challenges in maintaining profitability amidst rising administrative expenses and reduced sales.
The most recent analyst rating on (HK:1110) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Kingworld Medicines Group Ltd. stock, see the HK:1110 Stock Forecast page.
Kingworld Medicines Group Ltd. announced an expected significant decrease in profits for the first half of 2025, with a projected drop of 70% to 75% compared to the same period in 2024. This decline is attributed mainly to a reduction in gross profit from the distribution of imported pharmaceutical and healthcare products in China, driven by a slowdown in market demand. Despite a slight increase in profits from its subsidiary Dong Di Xin, the company anticipates a loss of approximately RMB4.5 million for the period, compared to a profit of RMB30.7 million in the previous year.
The most recent analyst rating on (HK:1110) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Kingworld Medicines Group Ltd. stock, see the HK:1110 Stock Forecast page.
Kingworld Medicines Group Ltd. has announced a board meeting scheduled for August 27, 2025, to discuss and approve the unaudited interim results for the first half of the year and consider an interim dividend. This meeting is significant for stakeholders as it will provide insights into the company’s financial performance and potential returns, impacting its market positioning and shareholder value.
Kingworld Medicines Group Limited announced the resignation of Mr. Zhang Jianbin as an independent non-executive director, effective August 1, 2025. Mr. Zhang also stepped down from his roles as chairman of the remuneration committee and member of the audit and nomination committees, citing personal endeavors. Dr. Chu Xiaoping has been appointed as the new chairman of the remuneration committee. This change in board composition reflects the company’s ongoing adjustments in leadership roles, potentially impacting its governance structure.
Kingworld Medicines Group Ltd. has announced the composition of its board of directors and their respective roles, effective from August 1, 2025. The board includes both executive and independent non-executive directors, with Mr. Zhao Li Sheng serving as Chairman. The announcement outlines the members of three key board committees: Audit, Remuneration, and Nomination, with specific directors assigned to each committee. This restructuring is likely to influence the company’s governance and strategic direction, potentially impacting its operational efficiency and stakeholder confidence.